United Kingdom

People: Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

16 Jul 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Drejer, Kirsten 

Dr. Kirsten Aarup Drejer has been Independent Vice Chairman of the Board at ZEALAND PHARMA A/S since April 4, 2019. She has been Independent Director of the Company since April 19, 2018. She holds PhD in Pharmacology and a MSc in Pharmacy from the University of Copenhagen. Kirsten Drejer is co-founder and previous CEO of Symphogen A/S (2000-2016) which is a privately biotech company dedicated to the development of mAb mixtures to provide effective treatments to serious diseases including with oncology. Dr. Drejer holds more than 30 years of international experience in the pharmaceutical and biotech industry. Before co-founding Symphogen A/S in 2000, Kirsten Drejer held several scientific and managerial positions at Novo Nordisk A/S, including four years as Director of Diabetes Discovery, and three years as Corporate Facilitator. She is Chairman of the board of Antag Therapeutics, Bioneer and Resother Pharma, and Board member of Bioporto, Lyhne & Co.

Basic Compensation

Total Annual Compensation, DKK 200,000
Restricted Stock Award, DKK --
Long-Term Incentive Plans, DKK --
All Other, DKK --
Fiscal Year Total, DKK 200,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --